Year |
Citation |
Score |
2016 |
Stout KA, Dunn AR, Lohr KM, Alter SP, Cliburn RA, Guillot TS, Miller GW. Selective enhancement of dopamine release in the ventral pallidum of methamphetamine-sensitized mice. Acs Chemical Neuroscience. PMID 27501345 DOI: 10.1021/Acschemneuro.6B00131 |
0.555 |
|
2015 |
Alter SP, Stout KA, Lohr KM, Taylor TN, Shepherd KR, Wang M, Guillot TS, Miller GW. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Experimental Neurology. PMID 26428905 DOI: 10.1016/J.Expneurol.2015.09.016 |
0.649 |
|
2014 |
Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America. 111: 9977-82. PMID 24979780 DOI: 10.1073/Pnas.1402134111 |
0.701 |
|
2014 |
Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology. 76: 97-105. PMID 24025942 DOI: 10.1016/J.Neuropharm.2013.08.033 |
0.771 |
|
2013 |
Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. Journal of Neurochemistry. 126: 591-603. PMID 23786406 DOI: 10.1111/Jnc.12345 |
0.685 |
|
2013 |
Alter SP, Lenzi GM, Bernstein AI, Miller GW. Vesicular integrity in Parkinson's disease. Current Neurology and Neuroscience Reports. 13: 362. PMID 23690026 DOI: 10.1007/S11910-013-0362-3 |
0.813 |
|
2013 |
Alter SP, Taylor TN, Sullivan P, Goldstein DS, Miller GW. Progressive Noradrenergic Degeneration in Mice with Reduced Expression of the Vesicular Monoamine Transporter (VMAT2) Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 125. DOI: 10.1016/B978-0-12-800044-1.00108-2 |
0.692 |
|
Low-probability matches (unlikely to be authored by this person) |
2013 |
Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, Mackerell AD, Tang LD, Qu CK. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Molecular Cancer Therapeutics. 12: 1738-48. PMID 23825065 DOI: 10.1158/1535-7163.Mct-13-0049-T |
0.259 |
|
2011 |
Paavola KJ, Stephenson JR, Ritter SL, Alter SP, Hall RA. The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. The Journal of Biological Chemistry. 286: 28914-21. PMID 21708946 DOI: 10.1074/Jbc.M111.247973 |
0.232 |
|
2009 |
Zheng H, Alter S, Qu CK. SHP-2 tyrosine phosphatase in human diseases. International Journal of Clinical and Experimental Medicine. 2: 17-25. PMID 19436828 |
0.132 |
|
Hide low-probability matches. |